Clinical Trials Search
Clinical Trial 19158
Cancer Type: Malignant Hematology
Study Type: Treatment
NCT#: NCT02862275
Phase: Early Phase I
Prinicipal Investigator: Frederick Locke
Study Title
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Summary
This phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread.
Objective
-To evaluate the safety of atezolizumab (MPDL3280A) administration in patients who have received ACT within 6 months of enrollment. -To evaluate the expansion of engrafted T cells following atezolizumab administration in the peripheral blood and within the tumor microenvironment. -To evaluate the phenotype and function of engrafted T cells following atezolizumab administration. -To observe and record anti-tumor activity. To evaluate the response rate using irRC and RECIST v1.1, or other tumor-specific criteria. -To evaluate survival outcomes and progression free survival using irRC and RECIST v1.1, or other tumor-specific criteria.
Therapies
Medications
Atezolizumab (Tecentriq)
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.